April 05, 2024 - AltPep Corporation , a privately held biotechnology company dedicated to early disease-modifying treatments and detection tools for amyloid diseases, announced that the peer-reviewed Nature journal Scientific Reports has published new results from the Company’s evaluation of its novel SOBA-AD blood test, aimed at detecting Alzheimer’s disease (AD).
The data, consistent with an earlier study, further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD. The SOBA-AD blood test targets toxic soluble oligomers, an early molecular trigger of amyloid diseases, with the ultimate goal of identifying patients with the disease years before symptoms manifest.
In the report titled “Performance of SOBA-AD blood test in discriminating Alzheimer’s disease patients from cognitively unimpaired controls in two independent cohorts”, 265 blinded plasma samples from two independent cohorts were tested at two different sites. The SOBA-AD blood test identified AD patients from cognitively unimpaired (CU) subjects with 100% sensitivity, >95% specificity, and >98% area under the curve (95% CI 0.95-1.00)... AltPep's Press Release -
